BHCM
APLS

Boulder Hill Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Boulder Hill Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,100
Closed -$367K – 131
2022
Q4 		$367K Buy
+7,100
New +$377K 0.3% 81

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boulder Hill Capital Management's APLS Position: Q1 2023 in Review

Boulder Hill Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2023, closing a stake of 7,100 shares — an estimated $367K sold.

Boulder Hill Capital Management first reported a position in APLS in Q4 2022 and held it in 1 quarter. The position peaked at $367K in Q4 2022. 281 funds tracked by Wall St. Rank hold APLS as of Q1 2023.

  • Boulder Hill Capital Management reported no remaining Apellis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Boulder Hill Capital Management sold 7,100 Apellis Pharmaceuticals shares in Q1 2023, an estimated $367K.
  • Boulder Hill Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Boulder Hill Capital Management's Apellis Pharmaceuticals position peaked at $367K in Q4 2022.
  • 281 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2023.

Based on Boulder Hill Capital Management's 13F filing for Q1 2023, filed 12 May 2023.